Nocion Therapeutics, a clinical-stage biopharmaceutical company, has raised $62 million in Series B funding.   Nocion is developing small molecule, permanently charged sodium channel blockers (CSCBs), called nocions, that selectively silence activated nociceptors for the treatment of serious conditions involving cough, itch, and pain. Proceeds from the financing will be used to evaluate the lead program, Taplucanium Dry Powder for Inhalation, in a Phase 2b study in Chronic Cough patients.   ...